摘要
目的探究黄芩泻白散加减治疗支气管扩张症急性加重期(肝火犯肺证)的临床疗效及对患者基质金属蛋白酶的影响。方法选取2017年9月至2019年9月鹤山市中医院收治的130例支气管扩张症急性加重期(肝火犯肺证)患者作为研究对象,根据随机抽签法分为观察组与对照组,各65例。观察组采取黄芩泻白散加减治疗,对照组采取常规盐酸莫西沙星片治疗,比较两组临床疗效、治疗前后基质金属蛋白酶-9(MMP-9)和基质金属蛋白酶抑制剂-1(TIMP-1)及临床指标(症状改善时间、住院时间)和不良反应发生率。结果观察组治疗总有效率为93.85%,高于对照组的76.92%,差异有统计学意义(P<0.05)。治疗后,两组MMP-9水平均低于治疗前,TIMP-1水平高于治疗前,且观察组MMP-9水平低于对照组,TIMP-1水平高于对照组,差异有统计学意义(P<0.05)。观察组症状改善时间、住院时间均短于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为4.62%,低于对照组的18.46%,差异有统计学意义(P<0.05)。结论黄芩泻白散加减治疗支气管扩张症急性加重期(肝火犯肺证)疗效显著,可改善患者TIMP-1、MMP-9水平,缩短症状改善时间、住院时间,促进患者康复,值得临床推广应用。
Objective To explore the clinical efficacy of Huangqin Xiebai powder in the treatment of acute exacerbation of bronchiectasis(liver fire invading lung syndrome)and its effect on matrix metalloproteinase in patients.Methods A total of 130 patients with acute exacerbation of bronchiectasis(liver fire invading lung syndrome)admitted to Heshan Hospital of Traditional Chinese Medicine from September 2017 to September 2019 were selected as the research subjects,they were divided into the observation group and the control group according to the random lottery method,with 65 cases in each group.The observation group was treated with Huangqin Xiebai powder,and the control group was treated with conventional moxifloxacin hydrochloride tablets,the clinical efficacy,matrix metalloproteinase-9(MMP-9)and tissue inhibitors of metalloprotejnasel-1(TIMP-1)before and after treatment,clinical indicators(symptom improvement time,hospitalization time)and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.85%,which was higher than 76.92%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of MMP-9 of the two groups were lower than those before treatment,the levels of TIMP-1 were higher than those before treatment,and the levels of MMP-9 in the observation group were lower than those in the control group,the levels of TIMP-1 were higher than those in the control group,the differences were statistically significant(P<0.05).The symptom improvement time and hospitalization time in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 4.62%,which was lower than 18.46%in the control group,and the difference was statistically significant(P<0.05).Conclusion Huangqin Xiebai powder has a significant therapeutic effect on the acute exacerbation of bronchiectasis(liver
作者
李健珍
LI Jianzhen(First Department of Internal Medicine,Heshan Hospital of Traditional Chinese Medicine,Jiangmen,Guangdong,529700,China)
出处
《当代医学》
2024年第15期156-158,共3页
Contemporary Medicine
关键词
黄芩泻白散加减
支气管扩张症急性加重期
肝火犯肺证
Addition and subtraction Huangqin Xiebai powder
Acute exacerbation of bronchiectasis
Liver fire invading lung syndrome
